Key Summary
- Mankind Pharma buys rights to Roche’s epilepsy drug Rivotril in India.
- Drug helps with seizures, panic and muscle relaxation.
- Move strengthens Mankind’s focus on long-term and specialty treatments.
Mankind Pharma has acquired the exclusive rights to manufacture, market and distribute Swiss pharma major Roche’s epilepsy drug Rivotril in India for an undisclosed amount.
The Delhi-based company aims to expand its focus on chronic pain and specialty therapies via these licensing partnerships and portfolio additions.
Roche is a leader in neurologic and psychiatric care in India. Rivotril, a clonazepam-based therapy, helps manage seizures, tackle panic disorder, and relax muscles, as it calms the overactive nerve signals in the brain. It is regarded as a reference brand with a strong clinical legacy.
Mankind’s senior president, Sales and Marketing, Atish Majumdar, said the acquisition aligns with their strategic focus on strengthening presence in chronic and specialty therapies.
